FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Philippe Delagrange

Research Profile

Chemicals & Drugs

Living Beings

Concepts & Ideas

Structure-Activity Relationship

Anatomy

Physiology

Binding, Competitive

Occupations

Drug Design

Co-author Network

Publications

TOP 3
Laurence Morellato; Pierre Renard; Daniel-Henri Caignard; Philippe Delagrange; Michel Langlois; Marie Lefas-Le Gall; Monique Mathé-Allainmat
Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors.
Céline Legros; Ulrich Matthey; Olivier Nosjean; Sandrine Pedragona-Moreau; Franck Suzenet; Emmanuel Thomas; Saïd Yous; Pascal Berthelot; Jean-Louis Brayer; Daniel-Henri Caignard; Philippe Delagrange; Benoît Folleas; Teresa Grelak; Gérald Guillaumet; Werner Hassler; François Lefoulon; Jean A Boutin
New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors.
Séverine Devavry; Céline Legros; Benoît Malpaux; Jean A Boutin; Chantal Brasseur; William Cohen; Philippe Delagrange; Gilberto Spadoni; Olivier Nosjean
Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Philippe Delagrange (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Laurence Morellato; Pierre Renard; Daniel-Henri Caignard; Philippe Delagrange; Michel Langlois; Marie Lefas-Le Gall; Monique Mathé-Allainmat
Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors.
Bioorganic & medicinal chemistry letters 2013;23(2):430-4.
2013: Céline Legros; Ulrich Matthey; Olivier Nosjean; Sandrine Pedragona-Moreau; Franck Suzenet; Emmanuel Thomas; Saïd Yous; Pascal Berthelot; Jean-Louis Brayer; Daniel-Henri Caignard; Philippe Delagrange; Benoît Folleas; Teresa Grelak; Gérald Guillaumet; Werner Hassler; François Lefoulon; Jean A Boutin
New Radioligands for Describing the Molecular Pharmacology of MT1 and MT2 Melatonin Receptors.
International journal of molecular sciences 2013;14(5):8948-62.
2012: Séverine Devavry; Céline Legros; Benoît Malpaux; Jean A Boutin; Chantal Brasseur; William Cohen; Philippe Delagrange; Gilberto Spadoni; Olivier Nosjean
Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists.
Journal of pineal research 2012;53(1):29-37.
2012: Mohamed Ettaoussi; Marouan Rami; Pierre Renard; Ahmed Sabaouni; Michael Spedding; Pascal Berthelot; Jean A Boutin; Daniel-Henri Caignard; Philippe Delagrange; Saïd Yous
Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).
European journal of medicinal chemistry 2012;49():310-23.
2012: Séverine Devavry; Sophie-Pénélope Guenin; Céline Legros; Benoît Malpaux; Olivier Nosjean; C Ouvry; Chantal Brasseur; Francis Cogé; William Cohen; Philippe Delagrange; Jean A Boutin
Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂.
European journal of pharmacology 2012;677(1-3):15-21.
2012: Marouan Rami; Pascal Berthelot; Koussayla Boukhalfa; Daniel-Henri Caignard; Philippe Delagrange; Mohamed Ettaoussi; Elodie Landagaray; Saïd Yous
Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands.
Molecules (Basel, Switzerland) 2012;18(1):154-66.
2011: Karine Reybier; Pierre Perio; Jalloul Bouajila; Jean A Boutin; Philippe Delagrange; Gilles Ferry; Françoise Nepveu
Insights into the redox cycle of human quinone reductase 2.
Free radical research 2011;45(10):1184-95.
2011: Saïd El Kazzouli; Amaury Griffon du Bellay; Sabine Berteina-Raboin; Daniel-Henri Caignard; Philippe Delagrange; Gérald Guillaumet
Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands.
European journal of medicinal chemistry 2011;46(9):4252-7.
2011: Christophe Mésangeau; Mikaël Fraise; Philippe Delagrange; Daniel-Henri Caignard; Jean A Boutin; Pascal Berthelot; Saïd Yous
Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.
European journal of medicinal chemistry 2011;46(5):1835-40.
2011: Véronique Leclerc; Mohamed Ettaoussi; Marouan Rami; Amaury Farce; Jean A Boutin; Philippe Delagrange; Daniel-Henri Caignard; Pierre Renard; Pascal Berthelot; Saïd Yous
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
European journal of medicinal chemistry 2011;46(5):1622-9.
2011: Matthieu Jeanty; Franck Suzenet; Philippe Delagrange; Olivier Nosjean; Jean A Boutin; Daniel-Henri Caignard; Gérald Guillaumet
Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
Bioorganic & medicinal chemistry letters 2011;21(8):2316-9.
2010: Pascal Maurice; Avais M Daulat; Rostislav Turecek; Klara Ivankova-Susankova; Francesco Zamponi; Maud Kamal; Nathalie Clement; Jean-Luc Guillaume; Bernhard Bettler; Céline Galès; Philippe Delagrange; Ralf JOckers
Molecular organization and dynamics of the melatonin MT₁ receptor/RGS20/G(i) protein complex reveal asymmetry of receptor dimers for RGS and G(i) coupling.
The EMBO journal 2010;29(21):3646-59.
2010: Charles-Etienne Benoit; Stephane Bastianetto; Jonathan Brouillette; YiuChung Tse; Jean A Boutin; Philippe Delagrange; TakPan Wong; Philippe Sarret; Rémi Quirion
Loss of quinone reductase 2 function selectively facilitates learning behaviors.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2010;30(38):12690-700.
2010: Gilles Ferry; Sabrina Hecht; Sylvie Berger; Natacha Moulharat; F Coge; Gérald Guillaumet; Véronique Leclerc; Saïd Yous; Philippe Delagrange; Jean A Boutin
Old and new inhibitors of quinone reductase 2.
Chemico-biological interactions 2010;186(2):103-9.
2010: Christophe Mésangeau; Basile Pérès; Carole Descamps-François; Philippe CHAVATTE; Valérie Audinot; Sophie Coumailleau; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel-Henri Caignard; Pascal Berthelot; Saïd Yous
Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands.
Bioorganic & medicinal chemistry 2010;18(10):3426-36.
2010: Ludwig Vincent; William Cohen; Philippe Delagrange; Jean A Boutin; Olivier Nosjean
Molecular and cellular pharmacological properties of 5-methoxycarbonylamino-N-acetyltryptamine (MCA-NAT): a nonspecific MT3 ligand.
Journal of pineal research 2010;48(3):222-9.
2010: Anissa Sidibe; Amandine Mullier; Patty Chen; Marc Baroncini; Jean A Boutin; Philippe Delagrange; Xavier d'Anglemont de Tassigny; Ralf JOckers
Expression of the orphan GPR50 protein in rodent and human dorsomedial hypothalamus, tanycytes and median eminence.
Journal of pineal research 2010;48(3):263-9.
2009: Francis Cogé; S P Guenin; I Fery; M Migaud; S Devavry; C Slugocki; C Legros; C Ouvry; W Cohen; N Renault; Olivier Nosjean; B Malpaux; Philippe Delagrange; J A Boutin
The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor.
British journal of pharmacology 2009;158(5):1248-62.
2009: Amandine Descamps; Colette Rousset; Mark J Millan; Mark Millan; Michael Spedding; Philippe Delagrange; Raymond Cespuglio
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.
Psychopharmacology 2009;205(1):93-106.
2009: Sophie Durieux; Angéline Chanu; Christophe Bochu; Valérie Audinot; Sophie Coumailleau; Jean A Boutin; Philippe Delagrange; Daniel H Caignard; Caroline Bennejean; Pierre Renard; Daniel Lesieur; Pascal Berthelot; Saïd Yous
Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II.
Bioorganic & medicinal chemistry 2009;17(8):2963-74.
2008: Jean A Boutin; Estelle Marcheteau; Philippe Hennig; Natacha Moulharat; Sylvie Berger; Philippe Delagrange; Jean-Paul Bouchet; Gilles Ferry
MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate.
Journal of pineal research 2008;45(4):524-31.
2008: Sophie Poissonnier-Durieux; Mohamed Ettaoussi; Basile Pérès; Jean A Boutin; Valérie Audinot; Caroline Bennejean; Philippe Delagrange; Daniel-Henri Caignard; Pierre Renard; Pascal Berthelot; Daniel Lesieur; Saïd Yous
Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands.
Bioorganic & medicinal chemistry 2008;16(18):8339-48.
2008: Jean A Boutin; Carine Saunier; Sophie-Pénélope Guenin; Sylvie Berger; Natacha Moulharat; Arnaud Gohier; Philippe Delagrange; Francis Cogé; Gilles Ferry
Studies of the melatonin binding site location onto quinone reductase 2 by directed mutagenesis.
Archives of biochemistry and biophysics 2008;477(1):12-9.
2008: Pascal Maurice; Avais DAULAT; Cédric Broussard; Julien MOZO; Guilhem Clary; Françoise Hotellier; Philippe Chafey; Jean-Luc Guillaume; Gilles Ferry; Jean A Boutin; Philippe Delagrange; Luc Camoin; Ralf JOckers
A generic approach for the purification of signaling complexes that specifically interact with the carboxyl-terminal domain of G protein-coupled receptors.
Molecular & cellular proteomics : MCP 2008;7(8):1556-69.
2008: Valérie Audinot; Anne Bonnaud; Line Grandcolas; Marianne Rodriguez; Nadine Nagel; Jean-Pierre Galizzi; Ales Balik; Sophie Messager; David G Hazlerigg; Perry Barrett; Philippe Delagrange; Jean A Boutin
Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
Biochemical pharmacology 2008;75(10):2007-19.
2008: Mohamed Ettaoussi; Basile Péres; Fréderique Klupsch; Philippe Delagrange; Jean-A Boutin; Pierre Renard; Daniel-H Caignard; Philippe CHAVATTE; Pascal Berthelot; Daniel Lesieur; Saïd Yous
Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
Bioorganic & medicinal chemistry 2008;16(9):4954-62.
2007: Pascale Chomarat; Francis Cogé; Sophie-Pénélope Guénin; François Mailliet; Fanny Vella; Catherine Mallet; Stéphanie Giraudet; Nadine Nagel; stephane leonce; Gilles Ferry; Philippe Delagrange; Jean A Boutin
Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference.
Biochimie 2007;89(10):1264-75.
2007: Hassina Ould Hamouda; Patty Chen; Angélique Levoye; Nejla Sözer-Topçular; Avais DAULAT; Jean-Luc Guillaume; Rivka Ravid; Egemen Savaskan; Gilles Ferry; Jean A Boutin; Philippe Delagrange; Ralf JOckers; Pascal Maurice
Detection of the human GPR50 orphan seven transmembrane protein by polyclonal antibodies mapping different epitopes.
Journal of pineal research 2007;43(1):10-5.
2007: Céline Legros; Stéphanie Chalivoix; Cecilia Gabriel; Elisabeth Mocaer; Philippe Delagrange; Eberhard Fuchs; Benoît Malpaux
First evidence of melatonin receptors distribution in the suprachiasmatic nucleus of tree shrew brain.
Neuro endocrinology letters 2007;28(3):267-73.
2007: Avais DAULAT; Pascal Maurice; Carine Froment; Jean-Luc Guillaume; Cédric Broussard; Bernard Monsarrat; Philippe Delagrange; Ralf JOckers
Purification and identification of G protein-coupled receptor protein complexes under native conditions.
Molecular & cellular proteomics : MCP 2007;6(5):835-44.
2006: Jean-Claude Thiery; Didier Lomet; Michael Schumacher; Philippe Liere; Hélène Tricoire; Alain Locatelli; Philippe Delagrange; Benoît Malpaux
Concentrations of estradiol in ewe cerebrospinal fluid are modulated by photoperiod through pineal-dependent mechanisms.
Journal of pineal research 2006;41(4):306-12.
2006: Francesco Gentili; Nathalie Pizzinat; Catherine Ordener; Sophie Marchal-Victorion; Agnès Maurel; Robert Hofmann; Pierre Renard; Philippe Delagrange; Maria Pigini; angelo parini; Mario Giannella
3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor.
Journal of medicinal chemistry 2006;49(18):5578-86.
2006: Angélique Levoye; Julie Dam; Mohammed A Ayoub; Jean-Luc Guillaume; Cyril Couturier; Philippe Delagrange; Ralf JOckers
The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization.
The EMBO journal 2006;25(13):3012-23.
2006: Marie-Françoise Boussard; Sandrine Truche; Anne Rousseau-Rojas; Sylvie Briss; Sophie Descamps; Monique Droual; Michel Wierzbicki; Gilles Ferry; Valérie Audinot; Philippe Delagrange; Jean A Boutin
New ligands at the melatonin binding site MT(3).
European journal of medicinal chemistry 2006;41(3):306-20.
2006: Angélique Levoye; Ralf JOckers; Mohammed A Ayoub; Philippe Delagrange; Egemen Savaskan; Jean-Luc Guillaume
Are G protein-coupled receptor heterodimers of physiological relevance?--Focus on melatonin receptors.
Chronobiology international 2006;23(1-2):419-26.
2006: Philippe Delagrange; Jean A Boutin
Therapeutic potential of melatonin ligands.
Chronobiology international 2006;23(1-2):413-8.
2005: François Mailliet; Gilles Ferry; Fanny Vella; Sylvie Berger; Francis Cogé; Pascale Chomarat; Catherine Mallet; Sophie-Pénélope Guénin; Gérald Guillaumet; Marie-Claude Viaud-Massuard; Saïd Yous; Philippe Delagrange; Jean A Boutin
Characterization of the melatoninergic MT3 binding site on the NRH:quinone oxidoreductase 2 enzyme.
Biochemical pharmacology 2005;71(1-2):74-88.
2005: Fanny Vella; Gilles Ferry; Philippe Delagrange; Jean A Boutin
NRH:quinone reductase 2: an enzyme of surprises and mysteries.
Biochemical pharmacology 2005;71(1-2):1-12.
2005: Jean A Boutin; Valérie Audinot; Gilles Ferry; Philippe Delagrange
Molecular tools to study melatonin pathways and actions.
Trends in pharmacological sciences 2005;26(8):412-9.
2005: Gilles Ferry; Caroline Ubeaud; Pierre-Hervé Lambert; Sophie Bertin; Francis Cogé; Pascale Chomarat; Philippe Delagrange; Bernard Serkiz; Jean-Paul Bouchet; Roger J W Truscott; Jean A Boutin
Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase.
The Biochemical journal 2005;388(Pt 1):205-15.
2005: Jean A Boutin; Florence Chatelain-Egger; Fanny Vella; Philippe Delagrange; Gilles Ferry
Quinone reductase 2 substrate specificity and inhibition pharmacology.
Chemico-biological interactions 2005;151(3):213-28.
2005: Mabrouka Doghman; Philippe Delagrange; Marie-Claude Berthelon; Philippe Durand; Danielle Naville; Martine Bégeot
Sustained inhibitory effect of Agouti Related Protein on the ACTH-induced cortisol production by bovine cultured adrenal cells.
Regulatory peptides 2005;124(1-3):215-9.
2004: François Mailliet; Gilles Ferry; Fanny Vella; Kader Thiam; Philippe Delagrange; Jean A Boutin
Organs from mice deleted for NRH:quinone oxidoreductase 2 are deprived of the melatonin binding site MT3.
FEBS letters 2004;578(1-2):116-20.
2004: Gilles Ferry; Caroline Ubeaud; Claire Dauly; Julien MOZO; Sophie Guillard; Sylvie Berger; Sandrine Jimenez; Catherine Scoul; Gregory Leclerc; Saïd Yous; Philippe Delagrange; Jean A Boutin
Purification of the recombinant human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and comparison with AANAT from other species.
Protein expression and purification 2004;38(1):84-98.
2004: Marc Claret; Helena Corominola; Ignasi Canals; Belén Nadal; Alain Chavanieu; Bruno Pfeiffer; Pierre Renard; Carmen Gorostiaga; Philippe Delagrange; Gérard Grassy; Ramon Gomis
S 23521 decreases food intake and body weight gain in diet-induced obese rats.
Obesity research 2004;12(10):1596-603.
2004: Mohammed A Ayoub; Angélique Levoye; Philippe Delagrange; Ralf JOckers
Preferential formation of MT1/MT2 melatonin receptor heterodimers with distinct ligand interaction properties compared with MT2 homodimers.
Molecular pharmacology 2004;66(2):312-21.
2004: Carlos Larraya; Jérôme Guillard; Pierre Renard; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Marie-Claude Viaud-Massuard
Preparation of 4-azaindole and 7-azaindole dimers with a bisalkoxyalkyl spacer in order to preferentially target melatonin MT1 receptors over melatonin MT2 receptors.
European journal of medicinal chemistry 2004;39(6):515-26.
2004: Cyril Sarrauste de Menthière; Alain Chavanieu; Gérard Grassy; Stéphane Dalle; Guillermo Salazar; Alain Kervran; Bruno Pfeiffer; Pierre Renard; Philippe Delagrange; Dominique Manechez; David Bakes; Alain Ktorza; Bernard Calas
Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.
European journal of medicinal chemistry 2004;39(6):473-80.
2004: François Mailliet; Valérie Audinot; Benoît Malpaux; Anne Bonnaud; Philippe Delagrange; Martine Migaud; Perry Barrett; Marie-Claude Viaud-Massuard; Daniel Lesieur; François Lefoulon; Pierre Renard; Jean A Boutin
Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors.
Biochemical pharmacology 2004;67(4):667-77.
2004: François Dupuis; Olivier Régrigny; jeffrey atkinson; Patrick Limiñana; Philippe Delagrange; Elizabeth Scalbert; Jean-Marc Chillon
Impact of treatment with melatonin on cerebral circulation in old rats.
British journal of pharmacology 2004;141(3):399-406.
2004: Mabrouka Doghman; Philippe Delagrange; Antonine Blondet; Marie-Claude Berthelon; Philippe Durand; Danielle Naville; Martine Bégeot
Agouti-related protein antagonizes glucocorticoid production induced through melanocortin 4 receptor activation in bovine adrenal cells: a possible autocrine control.
Endocrinology 2004;145(2):541-7.
2004: Gilles Ferry; Caroline Ubeaud; Julien MOZO; Christophe Péan; Philippe Hennig; Marianne Rodriguez; Catherine Scoul; Anne Bonnaud; Olivier Nosjean; Jean-Pierre Galizzi; Philippe Delagrange; Pierre Renard; Jean-Paul Volland; Saïd Yous; Daniel Lesieur; Jean A Boutin
New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors.
European journal of biochemistry / FEBS 2004;271(2):418-28.
2003: Bénédicte Prunet-Marcassus; Mathieu Desbazeille; Arnaud Bros; Katie Louche; Philippe Delagrange; Pierre Renard; Louis Casteilla; Luc Pénicaud
Melatonin reduces body weight gain in Sprague Dawley rats with diet-induced obesity.
Endocrinology 2003;144(12):5347-52.
2003: Stephen T O'Rourke; Hana Hammad; Philippe Delagrange; Elizabeth Scalbert; Paul M Vanhoutte
Melatonin inhibits nitrate tolerance in isolated coronary arteries.
British journal of pharmacology 2003;139(7):1326-32.
2003: Valérie Audinot; François Mailliet; Chantal Lahaye-Brasseur; Anne Bonnaud; Aude Le Gall; Christophe Amossé; Sandra Dromaint; Marianne Rodriguez; Nadine Nagel; Jean-Pierre Galizzi; Benoît Malpaux; Gérald Guillaumet; Daniel Lesieur; François Lefoulon; Pierre Renard; Philippe Delagrange; Jean A Boutin
New selective ligands of human cloned melatonin MT1 and MT2 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2003;367(6):553-61.
2003: Oxana R Kunduzova; Ghislaine Escourrou; Marie-Helene Seguelas; Philippe Delagrange; France De La Farge; Claudie Cambon; angelo parini
Prevention of apoptotic and necrotic cell death, caspase-3 activation, and renal dysfunction by melatonin after ischemia/reperfusion.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2003;17(8):872-4.
2003: Isabelle Charton; Franck Suzenet; Jean A Boutin; Valérie Audinot; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Gérald Guillaumet
Synthesis of 5-substituted-2,3-dihydro-1,4-benzoxathiins: biological evaluation as melatonin receptors ligands.
Journal of enzyme inhibition and medicinal chemistry 2003;18(2):187-93.
2003: C Mesangeau; Saïd Yous; Philippe CHAVATTE; Gilles Ferry; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel Lesieur
Design, synthesis and in vitro evaluation of novel benzo[b]thiophene derivatives as serotonin N-acetyltransferase (AANAT) inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2003;18(2):119-25.
2003: Philippe Delagrange; J Atkinson; J A Boutin; Louis Casteilla; Daniel Lesieur; René Misslin; S Pellissier; Luc Pénicaud; Pierre Renard
Therapeutic perspectives for melatonin agonists and antagonists.
Journal of neuroendocrinology 2003;15(4):442-8.
2003: Carole Descamps-François; Saïd Yous; Philippe CHAVATTE; Valérie Audinot; Anne Bonnaud; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel Lesieur
Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.
Journal of medicinal chemistry 2003;46(7):1127-9.
2003: Cécile Pégurier; Laurence Morellato; Eminn Chahed; Jean Andrieux; Jean-Paul Nicolas; Jean A Boutin; Caroline Bennejean; Philippe Delagrange; Michel Langlois; Monique Mathé-Allainmat
Synthesis of new arylalkoxy amido derivatives as melatoninergic ligands.
Bioorganic & medicinal chemistry 2003;11(5):789-800.
2003: Saïd Yous; Sophie Durieux-Poissonnier; Emmanuelle Lipka-Belloli; Halim Guelzim; Christophe Bochu; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Pierre Renard; Daniel Lesieur
Design and synthesis of 3-phenyl tetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands.
Bioorganic & medicinal chemistry 2003;11(5):753-9.
2003: Bruno Pitrosky; Philippe Delagrange; Marie-Claire Rettori; Paul Pevet
S22153, a melatonin antagonist, dissociates different aspects of photoperiodic responses in Syrian hamsters.
Behavioural brain research 2003;138(2):145-52.
2002: N Beaurain; C Mésangeau; Philippe CHAVATTE; Gilles Ferry; Valérie Audinot; Jean A Boutin; Philippe Delagrange; Caroline Bennejean; Saïd Yous
Design, synthesis and in vitro evaluation of novel derivatives as serotonin N-acetyltransferase inhibitors.
Journal of enzyme inhibition and medicinal chemistry 2002;17(6):409-14.
2002: Janice E Drew; Perry Barrett; Shaun Conway; Philippe Delagrange; Peter J Morgan
Differential coupling of the extreme C-terminus of G protein alpha subunits to the G protein-coupled melatonin receptors.
Biochimica et biophysica acta 2002;1592(2):185-92.
2002: Gilles Ferry; Julien MOZO; Caroline Ubeaud; S Berger; M Bertrand; Anne Try; Philippe Beauverger; C Mesangeau; Philippe Delagrange; Jean A Boutin
Characterization and regulation of a CHO cell line stably expressing human serotonin N-acetyltransferase (EC 2.3.1.87).
Cellular and molecular life sciences : CMLS 2002;59(8):1395-405.
2002: Valérie Wallez; Sophie Durieux-Poissonnier; Philippe CHAVATTE; Jean A Boutin; Valérie Audinot; Jean-Paul Nicolas; Caroline Bennejean; Philippe Delagrange; Pierre Renard; Daniel Lesieur
Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.
Journal of medicinal chemistry 2002;45(13):2788-800.
2002: Véronique Leclerc; Saïd Yous; Philippe Delagrange; Jean A Boutin; Pierre Renard; Daniel Lesieur
Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3).
Journal of medicinal chemistry 2002;45(9):1853-9.
2001: Olivier Régrigny; François Dupuis; jeffrey atkinson; Patrick Limiñana; Elizabeth Scalbert; Philippe Delagrange; Jean-Marc Chillon
Cerebral arteriolar structure and function in pinealectomized rats.
American journal of physiology. Heart and circulatory physiology 2001;281(4):H1476-80.
2001: Olivier Régrigny; Philippe Delagrange; Elizabeth Scalbert; jeffrey atkinson; Jean-Marc Chillon
Melatonin increases pial artery tone and decreases the lower limit of cerebral blood flow autoregulation.
Fundamental & clinical pharmacology 2001;15(4):233-8.
2001: R Rezaie; B Joseph; J B Bremner; Philippe Delagrange; C Kopp; René Misslin; Bruno Pfeiffer; Pierre Renard; Gérald Guillaumet
5-substituted 3,4-dihydro-3-amino-2H-1-benzopyran derivatives: synthesis and interaction with serotoninergic receptors.
The Journal of pharmacy and pharmacology 2001;53(7):959-68.
2001: Olivier Nosjean; J P Nicolas; F Klupsch; Philippe Delagrange; Emmanuel Canet; Jean A Boutin
Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2 .
Biochemical pharmacology 2001;61(11):1369-79.
2001: Janice E Drew; Perry Barrett; Julian G Mercer; Kim M Moar; E Canet; Philippe Delagrange; Peter J Morgan
Localization of the melatonin-related receptor in the rodent brain and peripheral tissues.
Journal of neuroendocrinology 2001;13(5):453-8.
2001: Shaun Conway; ES Mowat; Janice E Drew; Perry Barrett; Philippe Delagrange; Peter J Morgan
Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor.
Biochemical and biophysical research communications 2001;282(5):1229-36.
2001: I Baglin; Cyril Daveu; Jean-Charles Lancelot; Ronan Bureau; François Dauphin; Bruno Pfeiffer; Pierre Renard; Philippe Delagrange; Sylvain Rault
First tricyclic oximino derivatives as 5-HT3 ligands.
Bioorganic & medicinal chemistry letters 2001;11(4):453-7.
2001: C Vandeputte; Philippe Giummelly; jeffrey atkinson; Philippe Delagrange; Elizabeth Scalbert; Christine Capdeville-Atkinson
Melatonin potentiates NE-induced vasoconstriction without augmenting cytosolic calcium concentration.
American journal of physiology. Heart and circulatory physiology 2001;280(1):H420-5.
2001: Q Yang; E Scalbert; Philippe Delagrange; P M Vanhoutte; Stephen T O'Rourke
Melatonin potentiates contractile responses to serotonin in isolated porcine coronary arteries.
American journal of physiology. Heart and circulatory physiology 2001;280(1):H76-82.
2000: A Merle; J L Faucheron; Philippe Delagrange; Pierre Renard; M Roche; S Pellissier
Nycthemeral variations of cholecystokinin action on intestinal motility in rats: effects of melatonin and S 20928, a melatonin receptor antagonist.
Neuropeptides 2000;34(6):385-91.
2000: C Jellimann; Monique Mathé-Allainmat; Jean Andrieux; S Kloubert; Jean A Boutin; Jean-Paul Nicolas; Caroline Bennejean; Philippe Delagrange; Michel Langlois
Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors.
Journal of medicinal chemistry 2000;43(22):4051-62.
2000: Olivier Nosjean; M Ferro; F Coge; Philippe Beauverger; JM Henlin; François Lefoulon; JL Fauchere; Philippe Delagrange; Emmanuel Canet; Jean A Boutin
Identification of the melatonin-binding site MT3 as the quinone reductase 2.
The Journal of biological chemistry 2000;275(40):31311-7.
2000: A Merle; Philippe Delagrange; Pierre Renard; Daniel Lesieur; Jean-Claude Cuber; M Roche; S Pellissier
Effect of melatonin on motility pattern of small intestine in rats and its inhibition by melatonin receptor antagonist S 22153.
Journal of pineal research 2000;29(2):116-24.
2000: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; René Misslin
Anxiolytic-like properties of melatonin receptor agonists in mice: involvement of mt1 and/or MT2 receptors in the regulation of emotional responsiveness.
Neuropharmacology 2000;39(10):1865-71.
2000: Shaun Conway; Janice E Drew; ES Mowat; Perry Barrett; Philippe Delagrange; Peter J Morgan
Chimeric melatonin mt1 and melatonin-related receptors. Identification of domains and residues participating in ligand binding and receptor activation of the melatonin mt1 receptor.
The Journal of biological chemistry 2000;275(27):20602-9.
2000: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; René Misslin
Reentrainment of the spontaneous locomotor activity rhythm to a daylight reversal in C57BL/6 and C3H/He mice: implication of melatonin.
Physiology & behavior 2000;70(1-2):171-6.
2000: Gilles Ferry; Armelle Loynel; Nathalie Kucharczyk; Sophie Bertin; Marianne Rodriguez; Philippe Delagrange; Jean-Pierre Galizzi; E Jacoby; Jean-Paul Volland; Daniel Lesieur; Pierre Renard; Emmanuel Canet; Jean-Luc Fauchère; Jean A Boutin
Substrate specificity and inhibition studies of human serotonin N-acetyltransferase.
The Journal of biological chemistry 2000;275(12):8794-805.
2000: Shaun Conway; SJ Canning; HE Howell; ES Mowat; Perry Barrett; Janice E Drew; Philippe Delagrange; Daniel Lesieur; Peter J Morgan
Characterisation of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay.
European journal of pharmacology 2000;390(1-2):15-24.
2000: Cécile Pégurier; S Curtet; Jean-Paul Nicolas; Jean A Boutin; Philippe Delagrange; Pierre Renard; Michel Langlois
Synthesis of a small library of phenylalkylamide derivatives as melatoninergic ligands for human mt1 and MT2 receptors.
Bioorganic & medicinal chemistry 2000;8(1):163-71.
2000: I Charton; A Mamai; Caroline Bennejean; Pierre Renard; E H Howell; B Guardiola-Lemaître; Philippe Delagrange; P J Morgan; MC Viaud; Gérald Guillaumet
Substituted oxygenated heterocycles and thio-analogues: synthesis and biological evaluation as melatonin ligands.
Bioorganic & medicinal chemistry 2000;8(1):105-14.
2000: Jean A Boutin; Chantal Lahaye; C Pegurier; Jean-Paul Nicolas; JL Fauchere; M Langlois; Pierre Renard; Philippe Delagrange; Emmanuel Canet
Screening of ligand binding on melatonin receptor using non-peptide combinatorial libraries.
Journal of receptor and signal transduction research 2000;20(1):105-18.
1999: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; Pierre Renard; Daniel Lesieur; René Misslin
Regulation of emotional behaviour by day length in mice: implication of melatonin.
Behavioural pharmacology 1999;10(8):747-52.
1999: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; Pierre Renard; Daniel Lesieur; René Misslin
Antagonistic effects of S 22153, a new mt1 and MT2 receptor ligand, on the neophobia-reducing properties of melatonin in BALB/c mice.
Pharmacology, biochemistry, and behavior 1999;64(1):131-6.
1999: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; B Guardiola-Lemaître; René Misslin
Effects of melatonin on neophobic responses in different strains of mice.
Pharmacology, biochemistry, and behavior 1999;63(4):521-6.
1999: Olivier Régrigny; Philippe Delagrange; Elizabeth Scalbert; I Lartaud-Idjouadiene; jeffrey atkinson; Jean-Marc Chillon
Effects of melatonin on rat pial arteriolar diameter in vivo.
British journal of pharmacology 1999;127(7):1666-70.
1999: P Paul; Chantal Lahaye; Philippe Delagrange; Jean-Paul Nicolas; Emmanuel Canet; Jean A Boutin
Characterization of 2-[125I]iodomelatonin binding sites in Syrian hamster peripheral organs.
The Journal of pharmacology and experimental therapeutics 1999;290(1):334-40.
1999: C Jellimann; Monique Mathé-Allainmat; Jean Andrieux; Pierre Renard; Philippe Delagrange; Michel Langlois
Melatonergic properties of the (+)- and (-)-enantiomers of N-(4-methoxy-2,3-dihydro-1H-phenalen-2-yl)amide derivatives.
Journal of medicinal chemistry 1999;42(6):1100-5.
1999: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; René Misslin
The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice.
Behavioural pharmacology 1999;10(1):73-83.
1998: Jean-Guy Bizot-Espiard; A Doublé; Béatrice Cousin; Daniel Lesieur; B Guardiola-Lemaître; Philippe Delagrange; Alain Ktorza; Luc Pénicaud
Lack of melatonin effects on insulin action in normal rats.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1998;30(12):711-6.
1998: Véronique Leclerc; E Fourmaintraux; Patrick Depreux; Daniel Lesieur; P Morgan; HE Howell; Pierre Renard; Daniel-Henri Caignard; Bruno Pfeiffer; Philippe Delagrange; B Guardiola-Lemaître; J Andrieux
Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands.
Bioorganic & medicinal chemistry 1998;6(10):1875-87.
1998: Berthe Vivien-Roels; André Malan; Marie-Claire Rettori; Philippe Delagrange; J P Jeanniot; Paul Pevet
Daily variations in pineal melatonin concentrations in inbred and outbred mice.
Journal of biological rhythms 1998;13(5):403-9.
1998: Mireille Masson-Pévet; J Recio; Hilda Guerrero; Elisabeth Mocaer; Philippe Delagrange; Béatrice Guardiola-Lemaitre; Paul Pevet
Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat.
Journal of pineal research 1998;25(3):172-6.
1998: Olivier Régrigny; Philippe Delagrange; Elizabeth Scalbert; jeffrey atkinson; I Lartaud-Idjouadiene
Melatonin improves cerebral circulation security margin in rats.
The American journal of physiology 1998;275(1 Pt 2):H139-44.
1998: Jean-Guy Bizot-Espiard; A Doublé; B Guardiola-Lemaitre; Philippe Delagrange; Alain Ktorza; Luc Pénicaud
Diurnal rhythms in plasma glucose, insulin, growth hormone and melatonin levels in fasted and hyperglycaemic rats.
Diabetes & metabolism 1998;24(3):235-40.
1998: C Kopp; Emanuel Vogel; Marie-Claire Rettori; Philippe Delagrange; B Guardiola-Lemaître; René Misslin
Effects of a daylight cycle reversal on locomotor activity in several inbred strains of mice.
Physiology & behavior 1998;63(4):577-85.
1998: E Fourmaintraux; Patrick Depreux; Daniel Lesieur; B Guardiola-Lemaître; Caroline Bennejean; Philippe Delagrange; HE Howell
Tetrahydronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors.
Bioorganic & medicinal chemistry 1998;6(1):9-13.
1997: S Le Gouic; C Atgié; N Viguerie-Bascands; N Hanoun; Dominique Larrouy; L Ambid; Serge Raimbault; Daniel Ricquier; Philippe Delagrange; B Guardiola-Lemaitre; Luc Pénicaud; Louis Casteilla
Characterization of a melatonin binding site in Siberian hamster brown adipose tissue.
European journal of pharmacology 1997;339(2-3):271-8.
1997: Shaun Conway; SJ Canning; Perry Barrett; B Guardiola-Lemaitre; Philippe Delagrange; Peter J Morgan
The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor.
Biochemical and biophysical research communications 1997;239(2):418-23.
1997: H Prunier; Sylvain Rault; Jean-Charles Lancelot; M Robba; Pierre Renard; Philippe Delagrange; Bruno Pfeiffer; Daniel-Henri Caignard; R Misslin; B Guardiola-Lemaitre; M Hamon
Novel and selective partial agonists of 5-HT3 receptors. 2. Synthesis and biological evaluation of piperazinopyridopyrrolopyrazines, piperazinopyrroloquinoxalines, and piperazinopyridopyrroloquinoxalines.
Journal of medicinal chemistry 1997;40(12):1808-19.
1997: Perry Barrett; Shaun Conway; Ralf JOckers; A D Strosberg; B Guardiola-Lemaitre; Philippe Delagrange; Peter J Morgan
Cloning and functional analysis of a polymorphic variant of the ovine Mel 1a melatonin receptor.
Biochimica et biophysica acta 1997;1356(3):299-307.
1997: Shaun Conway; Janice E Drew; SJ Canning; Perry Barrett; Ralf JOckers; A D Strosberg; B Guardiola-Lemaitre; Philippe Delagrange; Peter J Morgan
Identification of Mel1a melatonin receptors in the human embryonic kidney cell line HEK293: evidence of G protein-coupled melatonin receptors which do not mediate the inhibition of stimulated cyclic AMP levels.
FEBS letters 1997;407(1):121-6.